Products Trifluridine is commercially available in the form of eye drops and other products. This article relates to ocular therapy. Structure and properties Trifluridine (C10H11F3N2O5, Mr = 296.2 g/mol) is a fluorine derivative of thymidine and is therefore also known as trifluorothymidine. Effects Trifluridine (ATC S01AD02) has antiviral properties. It inhibits thymidic acid synthetase, viral … Trifluridine
Products Letermovir was approved in the United States in 2017 and in the EU and many countries in 2018 in tablet form and as an intravenous solution for injection (Prevymis). Structure and properties Letermovir (C29H28F4N4O4, Mr = 572.6 g/mol) Effects Letermovir (ATC J05AX18) has antiviral properties. The effects are due to inhibition of the CMV … Letermovir
Products Cidofovir was initially marketed in many countries as an infusion concentrate under the brand name Vistide (Gilead). It was approved in many countries in 1997 and had not been available since 2014. In 2017, a concentrate for the preparation of an infusion solution was approved (Sidovis). Structure and properties Cidofovir (C8H14N3O6P, Mr = 279.2 … Cidofovir
Products Telbivudine is commercially available in the form of film-coated tablets (Sebivo). It has been approved in many countries since 2006. The solution has been off the market since 2012. Structure and properties Telbivudine (C10H14N2O5, Mr = 242.2 g/mol) is a thymidine analog and a prodrug that is biotransformed in cells to the active metabolite … Telbivudine
Products Glecaprevir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with pibrentasvir in film-coated tablet form (Maviret). Structure and properties Glecaprevir (C38H46F4N6O9S, Mr = 838.9 g/mol) exists as a white crystalline powder. Effects Glecaprevir has antiviral properties. The effects are due to inhibition of the viral … Glecaprevir
Products Remdesivir is commercially available as a powder for a concentrate for the preparation of an infusion solution (Veklury, Gilead Sciences Inc, USA). Provisional approval was granted in many countries and in the EU in July 2020. On November 25, 2020, the approval will be granted. In the U.S., the drug was registered in October. … Remdesivir
Products Baloxavirmarboxil was approved in film-coated tablet form in Japan and the United States in 2018 and in many countries in 2020 (Xofluza). Structure and properties Baloxavirmarboxil (C27H23F2N3O7S, Mr = 571.5 g/mol) is a prodrug of baloxavir (synonym: baloxaviric acid). It is converted to the active drug by hydrolysis. It is practically insoluble in water. … Baloxavirmarboxil
Products Pibrentasvir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with glecaprevir in film-coated tablet form (Maviret). Structure and properties Pibrentasvir (C57H65F5N10O8, Mr = 1113.2 g/mol) exists as a white to slightly yellow crystalline powder. Effects Pibrentasvir has antiviral properties. The effects are due to binding … Pibrentasvir
Products Umifenovir is available in Russia, among other countries, in tablet, capsule, and syrup form without a doctor’s prescription (Arbidol). It was developed in the Soviet Union in the 1970s. The drug is not approved in the United States, Europe, and Switzerland. Structure and properties Umifenovir (C22H25BrN2O3S, Mr = 477.4 g/mol) is a brominated indole … Umifenovir
Products Adefovir is commercially available in tablet form (Hepsera). It has been approved in the United States since 2002, in the EU since 2003, and in many countries since 2004. It was actually originally developed to treat HIV infection, but was not approved for that purpose. Structure and properties Adefovir is present in the drug … Adefovir
Products In many countries, no drugs containing docosanol are on the market. In other countries, a cream is approved (eg, Erazaban, Abreva, 10%). Structure and properties -Docosanol (C22H46O, Mr = 326.6 g/mol) is a long-chain, unsaturated primary alcohol. The waxy solid is insoluble in water due to its high lipophilicity. Effects Docosanol (ATC D06BB11) has … Docosanol
Products Velpatasvir was approved in 2016 in fixed combination with the HCV polymerase inhibitor sofosbuvir in film-coated tablet form (Epclusa, Gilead). Another fixed combination is Vosevi with sofosbuvir and voxilaprevir. Structure and properties Velpatasvir (C49H54N8O8, Mr = 883.0 g/mol) Effects Velpatasvir has antiviral properties. The effects are due to binding to the viral protein NS5A … Velpatasvir
